Aptose Biosciences Showcases Clinical Data for Tuspetinib at ASH Meeting

Aptose Biosciences featured clinical data for its lead compound tuspetinib combined with standard dosing of venetoclax and azacitidine in a poster presentation at the 67th American Society of Hematology, ASH, Annual Meeting in Orlando, FL. Updated data from patients in the TUSCANY trial across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA. Key Findings and Messages: In newly diagnosed AML patients, TUS+VEN+AZA shows promising safety, tolerability and resilient efficacy, including MRD-negative remissions across a broad mutational spectrum; High-quality clinical responses: 90% across 40, 80 and 120 mg dose levels, 100% at the higher 80 mg and 120 mg dose levels, Observed in FLT3-WT, FLT3-ITD, and NPM1c genetic subgroups, Observed in biallelic TP53/complex karyotype and RAS adverse genetic subgroups, Observed in AML with MDS-related mutations; MRD negativity: 78% by central flow cytometry in responding subjects; TUS targets VEN resistance mechanisms; inhibits kinase-driven abnormal signaling; Two subjects transitioned to stem cell transplantation and both returned for TUS maintenance; TUS+VEN+AZA triplet therapy was well tolerated with no dose-limiting toxicities across all evaluable TUS dose levels; At the recently enrolled 160 mg dose level, preliminary findings show patients achieving early blast clearance with MRD-negativity and formal responses in the first few weeks of treatment.